APA (7th ed.) Citation

Ambrosini, M., Tougeron, D., Modest, D., Guimbaud, R., Kopetz, S., Decraecker, M., . . . Taieb, J. (2024). 66P Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Annals of Oncology, 35, S32. https://doi.org/10.1016/j.annonc.2024.05.077

Chicago Style (17th ed.) Citation

Ambrosini, M., et al. "66P Targeted Treatment (TT) After Immune Checkpoint Inhibitors (ICIs) in BRAF V600E Mutated (BRAFm) and Deficient Mismatch Repair or Microsatellite Instability High (dMMR/MSI-H) Metastatic Colorectal Cancer (mCRC)." Annals of Oncology 35 (2024): S32. https://doi.org/10.1016/j.annonc.2024.05.077.

MLA (9th ed.) Citation

Ambrosini, M., et al. "66P Targeted Treatment (TT) After Immune Checkpoint Inhibitors (ICIs) in BRAF V600E Mutated (BRAFm) and Deficient Mismatch Repair or Microsatellite Instability High (dMMR/MSI-H) Metastatic Colorectal Cancer (mCRC)." Annals of Oncology, vol. 35, 2024, p. S32, https://doi.org/10.1016/j.annonc.2024.05.077.